Hospice News November 18, 2024
The rationale behind the U.S. Justice Department’s lawsuit against Optum and Amedisys (Nasdaq: AMED) is multi-faceted, citing potential adverse impacts on competition, home-based care workers and payers.
Optum, a subsidiary of UnitedHealth Group (NYSE: UNH) in June 2023 penned its agreement to acquire Amedisys in an all-cash transaction of $101 per share, or about $3.3 billion. The transaction is expected to close this year. Last summer, DOJ began investigating potential antitrust concerns related to the deal, which culminated in a lawsuit filed last week.
The state attorneys general of Maryland, Illinois, New Jersey, and New York are also plaintiffs in the suit.
DOJ’s chief concern is that the combination of the two companies would dampen competition in the hospice and...
Today's Sponsors
Today's Sponsor